RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family

被引:90
作者
Eckfeld, K
Hesson, L
Vos, MD
Bieche, I
Latif, F
Clark, GI
机构
[1] NCI, Dept Cell & Canc Biol, Rockville, MD 20850 USA
[2] Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham, W Midlands, England
[3] Ctr Rene Huguenin, INSERM E0017, Lab Oncogenet, St Cloud, France
关键词
D O I
10.1158/0008-5472.CAN-04-2065
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activated Ras proteins interact with a broad range of effector proteins to induce a diverse series of biological consequences. Although typically associated with enhanced growth and transformation, activated Ras may also induce growth antagonistic effects such as senescence or apoptosis. It is now apparent that some of the growth-inhibitory properties of Ras are mediated via the RASSF family of Ras effector/tumor suppressors. To date, four members of this family have been identified (Nore1, RASSF1, RASSF2, and RASSF3). We now identify a fifth member of this group, RASSF4 (AD037). RASSF4 shows approximately 25% identity with RASSF1A and 60% identity with RASSF2. RASSF4 binds directly to activated K-Ras in a GTP-dependent manner via the effector domain, thus exhibiting the basic properties of a Ras effector. Overexpression of RASSF4 induces Ras-dependent apoptosis in 293-T cells and inhibits the growth of human tumor cell lines. Although broadly expressed in normal tissue, RASSF4 is frequently down-regulated by promoter methylation in human tumor cells. Thus, RASSF4 appears to be a new member of the RASSF family of potential Ras effector/tumor suppressors.
引用
收藏
页码:8688 / 8693
页数:6
相关论文
共 34 条
  • [1] Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours
    Agathanggelou, A
    Honorio, S
    Macartney, DP
    Martinez, A
    Dallol, A
    Radar, J
    Fullwood, P
    Chauhan, A
    Walker, R
    Shaw, JA
    Hosoe, S
    Lerman, MI
    Minna, JD
    Maher, ER
    Latif, F
    [J]. ONCOGENE, 2001, 20 (12) : 1509 - 1518
  • [2] Quantification of estrogen receptor α and β expression in sporadic breast cancer
    Bièche, I
    Parfait, B
    Laurendeau, I
    Girault, I
    Vidaud, M
    Lidereau, R
    [J]. ONCOGENE, 2001, 20 (56) : 8109 - 8115
  • [3] BURBEE DG, 2001, J NATL CANCER I, V93, P664
  • [4] Increasing complexity of Ras signaling
    Campbell, SL
    Khosravi-Far, R
    Rossman, KL
    Clark, GJ
    Der, CJ
    [J]. ONCOGENE, 1998, 17 (11) : 1395 - 1413
  • [5] Differential regulation of discrete apoptotic pathways by Ras
    Chen, CY
    Liou, J
    Forman, LW
    Faller, DV
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (27) : 16700 - 16709
  • [6] Clark G. J., 1993, GTPASES BIOL, DOI [10.1007/978-3-642-78267-1_18, DOI 10.1007/978-3-642-78267-1_18]
  • [7] CLARK GJ, 1999, SIGNALING NETWORKS C, P213
  • [8] The dark side of Ras: regulation of apoptosis
    Cox, AD
    Der, CJ
    [J]. ONCOGENE, 2003, 22 (56) : 8999 - 9006
  • [9] Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
    Dammann, R
    Li, C
    Yoon, JH
    Chin, PL
    Bates, S
    Pfeifer, GP
    [J]. NATURE GENETICS, 2000, 25 (03) : 315 - 319
  • [10] Ras signalling and apoptosis
    Downward, J
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (01) : 49 - 54